Method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -529.84% · OPTIONAL
· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTAtara Biotherapeutics, Inc.'s latest supported as-filed period reports revenue of $630,000, 96.4% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -529.84% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value -96.42% · CORE
Level · gp.fundamentals.operating_margin
Raw value -749.21% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 213.49% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 62.54% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Shares outstanding increased 42.9%; SBC / revenue moved 4660 bp higher.
2 evidence-backed componentsCash & equivalents changed -80.9% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
ATRA · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0000905148-26-004085SEC ↗4Aug 26, 2026Period Aug 17, 20260000905148-26-003960SEC ↗10-QAug 12, 2026Period Jun 30, 20260001193125-26-346885SEC ↗8-KAug 12, 2026Period Aug 12, 20260001193125-26-346857SEC ↗4Jul 24, 2026Period Jul 22, 20260001104659-26-086733SEC ↗8-KJun 26, 2026Period Jun 22, 20260001193125-26-285498SEC ↗4Jun 15, 2026Period Jun 11, 20260000905148-26-002951SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 4, 2026Filed Sep 4, 2026 | Cherry Brian NDirector | Open Market PurchaseDirect | 104,166 | $10 | $999,994 | Form 4 ↗ |
| Aug 17, 2026Filed Aug 26, 2026 | Nguyen AnhCoPresident and CEO | Open Market SaleDirect | 5,062 | $8 | $40,883 | Form 4 ↗ |
| Jul 22, 2026Filed Jul 24, 2026 | Redmile Group, LLCDirector | Option ExerciseIndirect | 101,089 | $0 | $0 | Form 4 ↗ |
| Jul 22, 2026Filed Jul 24, 2026 | Redmile Group, LLCDirector | Option ExerciseIndirect | 38,735 | $0 | $0 | Form 4 ↗ |
| Jul 22, 2026Filed Jul 24, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating cash flow changed +54.4% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Operating margin changed -76740 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Research & development changed -81.6% from the comparable as-filed period.
Revenue changed -96.4% from the comparable as-filed period.
Working capital changed -34.5% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Operating income changed -247.6% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change. This reverses 3 consecutive comparable moves in the opposite direction.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001213900-26-068264| Redmile Group, LLCDirector |
| Option ExerciseIndirect |
| 55,387 |
| $0 |
| $0 |
| Form 4 ↗ |
| Jul 22, 2026Filed Jul 24, 2026 | Redmile Group, LLCDirector | Option ExerciseIndirect | 195,211 | — | — | Form 4 ↗ |
| Jul 22, 2026Filed Jul 24, 2026 | Redmile Group, LLCDirector | Tax WithholdingIndirect | 60 | — | — | Form 4 ↗ |
| Jun 11, 2026Filed Jun 15, 2026 | Cherry Brian NDirector | Grant Or AwardDirect | 24,000 | $0 | $0 | Form 4 ↗ |
| Jun 9, 2026Filed Jun 11, 2026 | Fust Matthew KDirector | Grant Or AwardDirect | 12,000 | $0 | $0 | Form 4 ↗ |
| Jun 9, 2026Filed Jun 11, 2026 | Ciongoli Gregory AustinDirector | Grant Or AwardDirect | 12,000 | $0 | $0 | Form 4 ↗ |
| Jun 9, 2026Filed Jun 11, 2026 | HEIDEN WILLIAM KDirector | Grant Or AwardDirect | 12,000 | $0 | $0 | Form 4 ↗ |
| May 18, 2026Filed May 20, 2026 | Grant-Huerta YaninaChief Accounting Officer | Open Market SaleDirect | 2,414 | $9 | $22,036 | Form 4 ↗ |
| May 18, 2026Filed May 20, 2026 | Nguyen AnhCoPresident and CEO | Open Market SaleDirect | 5,241 | $9 | $47,845 | Form 4 ↗ |
| May 7, 2026Filed May 11, 2026 | EcoR1 Capital, LLCReporting owner | Open Market PurchaseIndirect | 507,407 | $9 | $4.7M | Form 4 ↗ |
| May 7, 2026Filed May 11, 2026 | Panacea Innovation LtdReporting owner | Open Market SaleIndirect | 313,446 | $10 | $3.2M | Form 4 ↗ |
| Mar 17, 2026Filed Mar 19, 2026 | Panacea Innovation LtdReporting owner | Option ExerciseIndirect | 259,163 | $0 | $26 | Form 4 ↗ |
| Mar 17, 2026Filed Mar 19, 2026 | Panacea Innovation LtdReporting owner | Tax WithholdingIndirect | 5 | $5 | $26 | Form 4 ↗ |
| Mar 17, 2026Filed Mar 19, 2026 | Panacea Innovation LtdReporting owner | Option ExerciseIndirect | 259,163 | $7 | $1.7M | Form 4 ↗ |
| Mar 9, 2026Filed Mar 11, 2026 | Nguyen AnhCoPresident and CEO | Grant Or AwardDirect | 81,100 | $0 | $0 | Form 4 ↗ |